Lexicon Pharmaceuticals Up 7% After EU Approval for Diabetes Treatment

Date : 04/29/2019 @ 4:40PM
Source : Dow Jones News
Stock : Sanofi (SNY)
Quote : 45.56  0.67 (1.49%) @ 10:29PM

Lexicon Pharmaceuticals Up 7% After EU Approval for Diabetes Treatment

Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart

6 Months : From Apr 2019 to Oct 2019

Click Here for more Lexicon Pharmaceuticals Charts.

By Michael Dabaie


Lexicon Pharmaceuticals Inc. (LXRX) was up 7.2% to $6.39 in heavier-than-average trading Monday.

The company said Friday that the European Commission granted marketing authorization for Zynquista, which was developed by Sanofi (SNY) and Lexicon. Zynquista is now approved in the European Union for treatment of adults with type 1 diabetes.

Lexicon said Zynquista also is currently being evaluated in a program of 11 clinical trials in adults with type 2 diabetes, including two trials in people living with type 2 diabetes and renal impairment, and two large cardiovascular outcomes trials.


Write to Michael Dabaie at michael.dabaie@wsj.com


(END) Dow Jones Newswires

April 29, 2019 11:25 ET (15:25 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest SNY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.